Epizyme, Inc. (NASDAQ:EPZM) – Oppenheimer Holdings decreased their FY2020 EPS estimates for shares of Epizyme in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann now forecasts that the biopharmaceutical company will earn $1.60 per share for the year, down from their previous estimate of $1.84. Oppenheimer Holdings has a “Buy” rating and a $26.00 price objective on the stock.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.08. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The company’s revenue for the quarter was up 2027.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.49) EPS. WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/21/fy2020-earnings-estimate-for-epizyme-inc-epzm-issued-by-oppenheimer-holdings.html.

Several other analysts have also recently issued reports on EPZM. ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a research report on Saturday, June 3rd. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Epizyme in a research report on Wednesday, June 7th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research report on Wednesday, June 7th. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the stock a “buy” rating in a research report on Monday, June 12th. Finally, Citigroup Inc. increased their price target on Epizyme from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, June 16th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $23.33.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palo Alto Investors LLC increased its holdings in Epizyme by 18.9% during the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after purchasing an additional 907,245 shares during the period. Vanguard Group Inc. increased its holdings in Epizyme by 6.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock worth $51,640,000 after purchasing an additional 200,982 shares during the period. State Street Corp increased its holdings in Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after purchasing an additional 658,727 shares during the period. Foresite Capital Management II LLC increased its holdings in Epizyme by 1.1% during the 1st quarter. Foresite Capital Management II LLC now owns 1,543,118 shares of the biopharmaceutical company’s stock worth $26,464,000 after purchasing an additional 16,481 shares during the period. Finally, Foresite Capital Management III LLC increased its holdings in Epizyme by 12.7% during the 1st quarter. Foresite Capital Management III LLC now owns 681,922 shares of the biopharmaceutical company’s stock worth $11,695,000 after purchasing an additional 76,683 shares during the period. Institutional investors own 83.74% of the company’s stock.

In other news, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $15.50, for a total value of $46,872.00. Following the sale, the chief financial officer now directly owns 40,529 shares in the company, valued at $628,199.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction dated Monday, September 18th. The stock was acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders sold a total of 48,024 shares of company stock valued at $706,722 over the last ninety days. Corporate insiders own 25.20% of the company’s stock.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.